Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update

Area of Science:

• Oncology
• Metabolism
• Clinical Trials

Background:

• Cancer cachexia significantly impacts patient quality of life, treatment tolerance, and survival, affecting 50%-80% of cancer patients.
• Current therapeutic strategies, including nutritional support and pharmacological agents, yield limited and inconsistent functional benefits.
• Existing methods for measuring muscle mass in clinical trials, such as CT scans, are inadequate as primary endpoints due to variability and lack of clinical correlation.

Purpose of the Study:

• To summarize key discussions from the Society on Cachexia and Wasting Disorders (SCWD) workshop regarding regulatory requirements and advancements in cachexia clinical trials.
• To highlight the challenges and evolving consensus on clinical trial endpoints for cachexia therapies.
• To review recent clinical trial data and emerging therapeutic candidates for managing cancer cachexia.

Main Methods:

• Summary of discussions from the SCWD Regulatory and Trial Update Workshop.
• Review of existing cachexia treatments and their efficacy.
• Analysis of presented clinical trial data (MENAC, TCMCB07, ART27.13, S-pindolol) and regulatory perspectives on trial endpoints.

Main Results:

• Existing cachexia treatments show mixed results, often failing to achieve consistent functional improvements.
• Regulatory bodies emphasize patient-reported outcomes, physical function, and morbidity-mortality as crucial endpoints, moving beyond isolated body composition measures.
• Emerging agents like TCMCB07 and ART27.13 show promise in stabilizing weight and improving caloric intake, while S-pindolol targets muscle mass and strength.

Conclusions:

• Effective cachexia therapies require a shift towards patient-centered goals and validated endpoints that reflect real-life functioning.
• Clinical trial designs must integrate objective functional measures and patient-reported outcomes to meet regulatory standards and demonstrate meaningful clinical benefit.
• Future research and development should focus on novel therapeutic mechanisms and multimodal interventions addressing the complex nature of cancer cachexia.